Deadline:
5/26/2022 |
Quality of Care Initiative to Improve the Treatment of Advanced or Metastatic Bladder Cancer Patients Request for Proposals (RFP) |
National Comprehensive Cancer Network |
Discipline:
- Curriculum Development
- Medical
- Medical - Clinical Science
|
Who's Eligible:
|
Award Amount:
$300,000 |
4/14/2022 |
Deadline:
9/28/2021 |
NCCN Lilly Request for Proposals (RFP) to Optimize Biomarker Driven Therapy in Lung and Thyroid Cancers |
National Comprehensive Cancer Network |
Discipline:
- Medical
- Medical - Basic Science
- Medical - Clinical Science
- Medical - Translational
|
Who's Eligible:
|
Award Amount:
See solicitation for details |
4/18/2022 |
Deadline:
6/21/2021 |
NCCN Pfizer Talazoparib Request for Proposals |
National Comprehensive Cancer Network |
Discipline:
- Medical
- Medical - Basic Science
- Medical - Clinical Science
|
Who's Eligible:
|
Award Amount:
See solicitation for details |
4/18/2022 |
Deadline:
5/14/2021 |
NCCN Pfizer and Astellas Enzalutamide Request for Proposals (RFP) Announcement |
National Comprehensive Cancer Network |
Discipline:
- Medical
- Medical - Basic Science
- Medical - Clinical Science
|
Who's Eligible:
|
Award Amount:
See solicitation for details |
4/18/2022 |
Deadline:
5/03/2021 |
NCCN AstraZeneca Early Stage NSCLC Request for Proposals |
National Comprehensive Cancer Network |
Discipline:
- Medical
- Medical - Clinical Science
|
Who's Eligible:
|
Award Amount:
See solicitation for details |
4/18/2022 |
Deadline:
4/19/2021 |
NCCN Request for Proposals (RFP): Phase I/II Clinical and/or Correlative Studies of the panHER Inhibitor Neratinib in the Treatment of Breast, Gastrointestinal, Lung, and Neurological Cancers |
National Comprehensive Cancer Network |
Discipline:
- Medical
- Medical - Clinical Science
|
Who's Eligible:
|
Award Amount:
See solicitation for details |
4/18/2022 |
Deadline:
1/19/2021 |
NCCN Request for Proposals (RFP): Phase I/II Clinical and Correlative/Preclinical Trials of Decitabine and Cedazuridine for Hematologic Malignancies and Solid Tumors |
National Comprehensive Cancer Network |
Discipline:
- Medical
- Medical - Clinical Science
|
Who's Eligible:
|
Award Amount:
See solicitation for details |
4/18/2022 |
Deadline:
9/09/2020 |
ADOPTION OF BIOSIMILARS IN ONCOLOGY |
National Comprehensive Cancer Network |
Discipline:
- Environmental & Life Sciences
- Medical
- Medical - Basic Science
- Medical - Clinical Science
- Medical - Translational
|
Who's Eligible:
|
Award Amount:
See solicitation for details |
4/18/2022 |
Deadline:
8/12/2020 |
NCCN/Pfizer Request for Proposals (RFP) Phase I/II Clinical Trials of Axitinib in the Treatment of Melanoma, Hepatocellular Carcinoma and Colorectal Cancer |
National Comprehensive Cancer Network |
Discipline:
- Medical
- Medical - Basic Science
- Medical - Clinical Science
- Medical - Translational
|
Who's Eligible:
|
Award Amount:
See solicitation for details |
4/18/2022 |
Deadline:
6/27/2022 |
NCCN and AstraZeneca Quality Improvement Initiative: Improving the Quality of Care and Application of Best Practices in the Treatment of Patients with Small Cell Lung Cancer (SCLC) |
National Comprehensive Cancer Network |
Discipline:
- Curriculum Development
- Medical
- Medical - Clinical Science
- Medical - Translational
|
Who's Eligible:
|
Award Amount:
See solicitation for details |
5/18/2022 |
Deadline:
8/18/2022 |
NCCN, Pfizer and EMD Serono Quality of Care Initiative to Improve the Treatment of Locally Advanced or Metastatic Bladder Cancer Patients |
National Comprehensive Cancer Network |
Discipline:
- Medical
- Medical - Clinical Science
- Medical - Translational
|
Who's Eligible:
|
Award Amount:
See solicitation for details |
7/13/2022 |
Deadline:
5/22/2023 |
NCCN Request for Proposals (RFP): Combination Therapy with Relugolix in the Treatment of Advanced Prostate Cancer |
National Comprehensive Cancer Network |
Discipline:
- Medical
- Medical - Basic Science
- Medical - Clinical Science
- Medical - Translational
|
Who's Eligible:
|
Award Amount:
See solicitation for details |
3/21/2023 |
Deadline:
5/10/2023 |
NCCN Request for Proposals (RFP): NCCN Pfizer Investigator-Sponsored Research Project to Evaluate the Effectiveness of Elranatamab in the Treatment of Multiple Myeloma |
National Comprehensive Cancer Network |
Discipline:
- Medical
- Medical - Clinical Science
|
Who's Eligible:
|
Award Amount:
$1,250,000 |
3/29/2023 |